Arisan Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.arisanthera.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Arisan Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06911242
- Locations
- 🇺🇸
Frontage, Secaucus, New Jersey, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Lassa Virus Infection
- Interventions
- Drug: ARN-75039 oral capsulesDrug: Placebo
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Arisan Therapeutics, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT05735249
- Locations
- 🇺🇸
Spaulding Clinical, LLC, West Bend, Wisconsin, United States
News
No news found